Lucid Diagnostics Inc. (LUCD) Financial Statements
Industry: Surgical & Medical Instruments & Apparatus
In fiscal 2025, Lucid Diagnostics reported revenue of $4.7M, up 8.3% from $4.3M the year before. Net income was -$58.0M (a -1232.7% net margin). Gross margin was -41.7% and operating margin was -1054.8%. Operating activities generated -$46.5M of cash, leaving -$46.7M of free cash flow. At fiscal year end, Lucid Diagnostics held $40.4M in total assets against $29.5M in total liabilities.
Open the full interactive Lucid Diagnostics financials → Quarterly statements, key ratios, valuation history and price charts.
Lucid Diagnostics Key Stats
| Share Price | $0.61 |
|---|---|
| Market Cap | $111.0M |
| Revenue YoY Growth | +8.3% |
| 52-Week Range | $0.59 – $1.47 |
| Shares Outstanding | 183.1 million (basic, 2026 Q2) |
Lucid Diagnostics Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $500,000 | $377,000 | $2.4M | $4.3M | $4.7M |
| Cost of Goods Sold | — | $100.0M | — | — | $54.3M |
| Gross Profit | -$85,000 | $377,000 | — | — | -$2.0M |
| Operating Income | -$27.4M | -$56.2M | -$48.5M | -$46.1M | -$49.6M |
| Pre-Tax Income | -$28.1M | -$56.2M | -$52.7M | -$45.5M | -$58.0M |
| Income Tax | — | — | — | — | $0 |
| Net Income | -$28.1M | -$56.2M | -$52.7M | -$45.5M | -$58.0M |
| Diluted EPS | -$1.51 | — | -$1.26 | -$1.05 | — |
Lucid Diagnostics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $1.2M | $1.5M | $1.3M | $1.5M |
| Net Income | -$10.4M | -$16.3M | -$13.9M | -$11.7M |
| Diluted EPS | -$0.10 | — | — | — |
Lucid Diagnostics Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | — | $22.5M | $18.9M | $22.4M | — |
| Current Assets | $57.3M | $24.4M | $22.1M | $25.1M | $37.5M |
| Total Assets | $59.0M | $32.5M | $27.3M | $30.7M | $40.4M |
| Current Liabilities | — | $8.4M | $29.4M | $23.5M | $28.6M |
| Total Liabilities | $4.3M | $9.5M | $29.6M | $25.3M | $29.5M |
| Shareholders' Equity | $54.7M | $23.0M | -$2.3M | $5.4M | $10.9M |
Lucid Diagnostics Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$17.7M | -$29.7M | -$32.8M | -$44.1M | -$46.5M |
| Cash From Investing | -$862,000 | -$4.1M | -$221,000 | -$646,000 | -$197,000 |
| Cash From Financing | $72.1M | $2.6M | $29.5M | $48.2M | $59.0M |
| Free Cash Flow | -$18.5M | -$32.9M | -$32.8M | -$44.1M | -$46.7M |
Figures from Lucid Diagnostics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Lucid Diagnostics financials page for every line item.
Lucid Diagnostics Company Profile
| Ticker | LUCD |
|---|---|
| Exchange | Nasdaq |
| Industry | Surgical & Medical Instruments & Apparatus |
| Headquarters | New York, New York |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001799011 |
Frequently Asked Questions
What was Lucid Diagnostics' revenue in fiscal 2025?
Lucid Diagnostics (LUCD) reported revenue of $4.7M for fiscal 2025.
What is Lucid Diagnostics' annual revenue history?
Lucid Diagnostics' annual revenue by fiscal year: 2021: $500,000; 2022: $377,000; 2023: $2.4M; 2024: $4.3M; 2025: $4.7M.
What was Lucid Diagnostics' net income in fiscal 2025?
Lucid Diagnostics reported net income of -$58.0M for fiscal 2025.
How much free cash flow did Lucid Diagnostics generate in fiscal 2025?
Lucid Diagnostics generated -$46.7M of free cash flow in fiscal 2025.
What was Lucid Diagnostics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Lucid Diagnostics reported revenue of $1.5M.
How many shares of Lucid Diagnostics are outstanding?
Lucid Diagnostics reported a weighted average of 183.1 million basic shares outstanding in 2026 Q2.
What is Lucid Diagnostics' market cap?
Based on its latest closing price, Lucid Diagnostics (LUCD) has a market capitalization of about $111.0M.
When does Lucid Diagnostics' fiscal year end?
Lucid Diagnostics' fiscal year end, as registered with the SEC, is December 31.
Where is Lucid Diagnostics headquartered?
Lucid Diagnostics lists its business address in New York, New York in its SEC filings.